undamentalytics Newsletter
Sign in

Fate Therapeutics Inc income statement

In fiscal 2025, Fate Therapeutics Inc reported revenue of $6.6m, down 51.2% on the year before, operating income of −$148m (a -2222.4% margin) and net income of −$136m, or −$1.15 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue131244511315696641476
Research and development1012122026345688126216320173135108100
General and administrative547101012162434578481744740
Operating income−13−14−18−28−32−42−67−101−128−217−308−191−210−148−134
Interest expense0012212200—————
Income tax———————0000000—
Net income−13−14−21−30−33−43−67−98−173−212−282−161−186−136−126
Diluted EPS−$16.16−$13.06−$3.54−$1.18−$1.05−$1.02−$1.19−$1.44−$2.10−$2.24−$2.91−$1.64−$1.64−$1.15−$1.05
Diluted shares (average)—1m6m25m32m42m56m68m82m95m97m98m114m119m120m
EBITDA−13−13−17−27−31−41−66−99−125−211−295−172−191−135−122

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FATE vs HCWBCGON vs FATEFATE vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fate Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fate Therapeutics Inc.